Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors

Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors

Abstract Background Immune checkpoint inhibitors (ICIs) have revolutionized the prognosis of cancer. Diabetes mellitus (DM) has been shown to have a negative effect on patients treated with ICIs. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are effective antidiabetic therapies associated with...

Full description

Bibliographic Details
Main Authors: Moran Gvili Perelman, Rafael Y. Brzezinski, Barliz Waissengrin, Yasmin Leshem, Or Bainhoren, Tammi Arbel Rubinstein, Maxim Perelman, Zach Rozenbaum, Ofer Havakuk, Yan Topilsky, Shmuel Banai, Ido Wolf, Michal Laufer-Perl
Format: Article
Language:English
Published: BMC 2024-01-01
Series:Cardio-Oncology
Subjects:
ICIs
SGLT2
Cardio-oncology
Cardiotoxicity
Immune checkpoint inhibitor
Diabetes
Online Access:https://doi.org/10.1186/s40959-023-00199-6

Internet

https://doi.org/10.1186/s40959-023-00199-6

Similar Items